Product Reports Resources Pricing Login Book a demo

Vyne Therapeutics

Biotech & Life Sciences · Menlo Park, United States · Founded 2011 · IPO 2018

Late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus MoreLess

VYNE Therapeutics is an entrepreneurial biopharmaceutical company focused on developing innovative and differentiated therapies to address some of the most difficult therapeutic challenges. The company leverages its existing development capabilities and a strong network of discovery and preclinical science partners to advance new medicines through the clinical pipeline. VYNE Therapeutics operates in the biopharmaceutical market, primarily serving patients with unmet medical needs. The business model revolves around the development and commercialization of proprietary therapies, generating revenue through product sales and potential partnerships or licensing agreements. The company's approach is rooted in questioning traditional assumptions and finding better solutions, driven by a culture of collaborative teamwork and independent thinking.

Keywords: biopharmaceutical, innovative therapies, proprietary, differentiated, clinical pipeline, unmet medical needs, product sales, partnerships, licensing, entrepreneurial.

Revenue $570K
Total funding $100–500M

Talent graph

Vyne Therapeutics's talent

Book a demo to see the people
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

10 investors on Vyne Therapeutics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 5 investors entered at this stage
CMEA Capital
Remeditex Ventures
Vivo Capital
Presidio Partners
F-Prime
Series B+ 5 investors entered at this stage
Aisling Capital
Bay City Capital
Rock Springs Capital
Novo Holdings
venBio Partners

Global footprint

Where Vyne Therapeutics has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

What the market is saying about Vyne Therapeutics

An AI-synthesized read of the highest-engagement posts about Vyne Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vyne Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.